Advances in peritoneal dialysis.

Area of Science:

• Nephrology
• Renal Replacement Therapy
• Dialysis Technology

Background:

• New peritoneal dialysis (PD) patients exhibit superior survival compared to new hemodialysis (HD) patients in the initial years of treatment.
• This initial survival advantage in PD is attributed to better preservation of residual renal function (rGFR), which offers benefits beyond dialysis, including improved uremic symptom management and quality of life.
• Conversely, long-term treatment survival shows an advantage for HD, highlighting a critical need to extend PD's benefits over time.

Purpose of the Study:

• To investigate the relationship between peritoneal dialysis transport status and patient survival.
• To explore the mechanisms linking fast peritoneal transport to increased mortality risk.
• To evaluate strategies for preserving residual renal function and improving long-term outcomes in peritoneal dialysis.

Main Methods:

• Meta-analysis of existing studies on peritoneal dialysis transport status and mortality.
• Analysis of factors contributing to inherent and acquired fast peritoneal transport.
• Review of clinical and animal studies on the efficacy of icodextrin-based and biocompatible dialysis solutions.

Main Results:

• A meta-analysis revealed a 15% increased mortality risk for fast transport patients on continuous ambulatory peritoneal dialysis (CAPD) with conventional solutions, likely linked to overhydration.
• Fast transport can be inherent (inflammatory state, large mesothelial cell mass) or acquired (developing in about one-third of patients, leading to ultrafiltration failure).
• Morphological peritoneal alterations, exacerbated by conventional dialysis solutions, contribute to acquired fast transport and associated excess mortality. Icodextrin solutions show promise for treating ultrafiltration failure.

Conclusions:

• Preserving residual renal function is paramount for improving PD patient survival and quality of life.
• Addressing fast peritoneal transport, particularly the acquired form linked to peritoneal alterations, is crucial for extending PD's survival advantage.
• Modern PD aims to enhance long-term outcomes through a better understanding of mechanisms and the development of advanced, biocompatible dialysis solutions.